Drug Information

Drug General Information
Drug ID
D05CEU
Former ID
DAP000142
Drug Name
Flunarizine
Synonyms
Flufenal; Flunarizin; Flunarizina; Flunarizinum; Fluvert; Issium; Sibelium; Vertix; Zinasen; Apo-flunarizine capsules; Flunarizina [INN-Spanish]; Flunarizine (INN); Flunarizine [INN:BAN]; Flunarizinum [INN-Latin]; Novo-Flunarizine; R-14950; Sibelium (TN); (E)-1-(Bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)piperazine; (E)-1-[Bis-(p-fluorophenyl)methyl]-4-cinnamylpiperazine; 1-(Bis(4-fluorophenyl)methyl)-4-cinnamylpiperazine; 1-[bis(4-fluorophenyl)methyl]-4-(3-phenylprop-2-en-1-yl)piperazine; 1-[bis(4-fluorophenyl)methyl]-4-[(E)-3-phenylprop-2-enyl]piperazine
Drug Type
Small molecular drug
Indication Migraine [ICD9: 346; ICD10:G43] Approved [538455]
Therapeutic Class
Anticonvulsants
Company
Janssen Pharmaceutica
Formula
C26H26F2N2
Canonical SMILES
C1CN(CCN1CC=CC2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)<br />F
InChI
1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+
InChIKey
SMANXXCATUTDDT-QPJJXVBHSA-N
CAS Number
CAS 52468-60-7
PubChem Compound ID
941361
PubChem Substance ID
7979238, 9208288, 10525243, 14879384, 26751607, 26751608, 44891609, 46507129, 47216516, 47216517, 47439976, 47515052, 47515053, 47515054, 47515055, 47588728, 47588729, 47736197, 48184716, 49698432, 50011452, 50104264, 50104265, 56365814, 57408889, 80028030, 81093273, 85787717, 85788409, 85788604, 90341204, 92308837, 92309757, 92711460, 96024666, 99300671, 99302189, 103050123, 103096316, 103153578, 103199419, 103928970, 104179181, 110096637, 117509719, 124526360, 124749784, 124883264, 124883265, 124883266
SuperDrug ATC ID
N07CA03
SuperDrug CAS ID
cas=052468607
Target and Pathway
Target(s) Voltage-dependent T-type calcium channel subunit alpha-1H Target Info Blocker [535918], [537585]
KEGG Pathway MAPK signaling pathway
Calcium signaling pathway
Circadian entrainment
PathWhiz Pathway Muscle/Heart Contraction
Reactome NCAM1 interactions
WikiPathways Corticotropin-releasing hormone
NCAM signaling for neurite out-growth
References
Ref 538455FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 012102.
Ref 535918Migraine prophylaxis with calcium antagonists: a haemodynamic study using transcranial Doppler ultrasound. Rev Neurol. 2004 Feb 16-29;38(4):316-9.
Ref 537585Positive Allosteric Interaction of Structurally Diverse T-Type Calcium Channel Antagonists. Cell Biochem Biophys. 2009 Jul 7.